Status:
RECRUITING
Immune Cells During Disuse and Recovery
Lead Sponsor:
University of Utah
Conditions:
Muscle Disuse
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
This is an interventional study enrolling healthy individuals aged 18-35 and 60-85 to understand the recovery of muscle health following a period of inactivity. The enrollment goal is 45 participants....
Detailed Description
Visit 1 (Pre-testing)- After signing a consent form, participants will undergo a blood screening and an oral glucose tolerance test. After the visit, participants will be provided with a step activity...
Eligibility Criteria
Inclusion
- Age between 18-35 and 60-85 yrs
- Ability to sign informed consent
- Free-living, prior to admission
Exclusion
- History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt)
- History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes
- History of kidney disease or failure
- Vascular disease
- Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III
- Use of anticoagulant therapy (e.g., Coumadin, heparin)
- Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
- Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)
- Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
- Currently on a weight-loss diet
- Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted)
- Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted)
- History of stroke with motor disability
- A recent history (\<12 months) of GI bleed
- History of liver disease
- History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
- Pregnancy as determined by a pregnancy test
- Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator.
- Any other condition or event considered exclusionary by the PI and faculty physician
Key Trial Info
Start Date :
May 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2028
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04416191
Start Date
May 15 2022
End Date
April 30 2028
Last Update
December 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Utah
Salt Lake City, Utah, United States, 84112